BOOK A DEMO

Sonic Incytes Accepted Into Boston CTA

Sonic Incytes Medical Corp. is pleased to announce it has been selected to participate in the Canadian Technology Accelerator (CTA) 2020 program, along with 10 other promising start-ups in tech and life sciences from across Canada. The program will take place in Boston and runs from May to November 2020.

The Boston CTA is an award-winning non-equity program that connects Canadian tech and life science companies to US clients, strategic partners and investors.

It emphasizes aggressive business development and growth. Located at the Cambridge Innovation Center, the program offers customized team mentoring from successful entrepreneurs, investors and industry leaders.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.

Julia PinterMarketing Director

Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.